|
|
![]() |
![]() |
![]() |
![]() |
|
![]() |
|
![]() |
|
![]() |
|
![]() |
![]() |
![]() |
|
![]() |
|||||||||||||||||||||||||||||||||||||||||||||
| Sponsored by: |
Merck |
| Information provided by: | Merck |
| ClinicalTrials.gov Identifier: | NCT00060476 |
Purpose
To determine the efficacy and safety of an investigational compound (MK0966) for the prevention of prostate cancer.
| Condition | Intervention | Phase |
|
Prostate Cancer |
Drug: rofecoxib Drug: Comparator: placebo (unspecified) |
Phase III |
| MedlinePlus related topics: | Cancer Prostate Cancer |
| Drug Information available for: | Rofecoxib |
| Study Type: | Interventional |
| Study Design: | Prevention, Randomized, Double Blind (Subject, Investigator), Placebo Control, Parallel Assignment, Safety/Efficacy Study |
| Official Title: | A Double-Blind, Randomized, Placebo-Controlled, Multicenter Study to Evaluate the Effects of Rofecoxib in Decreasing the Risk of Prostate Cancer (ViP Study) |
| Enrollment: | 15000 |
| Study Start Date: | June 2003 |
| Study Completion Date: | February 2005 |
The duration of treatment is 6 years.
Eligibility
| Ages Eligible for Study: | 50 Years to 75 Years |
| Genders Eligible for Study: | Male |
| Accepts Healthy Volunteers: | Yes |
Regular PSA testing and study biopsies required.
Contacts and Locations
More Information
| Responsible Party: | Merck & Co., Inc. ( Executive Vice President, Clinical and Quantitative Sciences ) |
| Study ID Numbers: | 2006_414, Formally-P30A03LD, MK0966-201 |
| First Received: | May 6, 2003 |
| Last Updated: | July 31, 2008 |
| ClinicalTrials.gov Identifier: | NCT00060476 |
| Health Authority: | United States: Food and Drug Administration |
|
|
|
|